Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price traded up 31% during trading on Friday . The company traded as high as C$0.23 and last traded at C$0.19. 480,687 shares were traded during trading, a decline of 9% from the average session volume of 525,664 shares. The stock had previously closed at C$0.15.
Hemostemix Price Performance
The company has a market cap of C$27.69 million, a price-to-earnings ratio of -5.54 and a beta of 0.20. The company’s 50 day moving average price is C$0.20 and its 200 day moving average price is C$0.12. The company has a current ratio of 0.04, a quick ratio of 0.48 and a debt-to-equity ratio of -55.07.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Articles
- Five stocks we like better than Hemostemix
- Value Investing: Is it a Good Strategy in 2022? (Hint: Always)
- As the Magnificent 7 Stalls, These 3 Stocks Are Gaining Momentum
- 3 Tickers Leading a Meme Stock Revival
- Gold’s Ascent: Can Miners and ETFs Take Investors to $3,000?
- Most Volatile Stocks, What Investors Need to Know
- Medtronic’s Expansion Gains Momentum—Time for a Market Shift?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
